This invention relates to compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the alpha7 receptor subtype with little or no activation of the alpha4beta2 or other receptor subtypes.
BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES AS NEURONAL NICOTINIC ALPHA-7 RECEPTOR AGONISTS